Treatment options for mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome

Pharmacotherapy

Volumn 30, Issue 11, 2010, Pages 1179-1196

  Santa, Kristin M ^a  

^a FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

Author keywords

Coenzyme Q10; Encephalopathy; L arginine; Lactic acidosis; MELAS syndrome; Mitochondria; Mitochondrial myopathy; Stroke like episodes

Indexed keywords

ALPHA TOCOPHEROL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ARGININE; ASCORBIC ACID; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARNITINE; CREATINE; CYTOCHROME C; DEXAMETHASONE; DICHLOROACETIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IDEBENONE; MENADIONE; METFORMIN; METHYLPREDNISOLONE; MITOCHONDRIAL DNA; NEUROMUSCULAR BLOCKING AGENT; NICOTINAMIDE; PLACEBO; PREDNISONE; PROPOFOL; RIBOFLAVIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SEROTONIN AGONIST; SUCCINIC ACID; THIAMINE; THIOCTIC ACID; UBIDECARENONE; UNINDEXED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACID BASE BALANCE; ANXIETY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC TEST; DIARRHEA; DIETARY INTAKE; DISEASE COURSE; DIZZINESS; DROWSINESS; DRUG CONTRAINDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EDEMA; ENDOCRINE DISEASE; EXERCISE; EYE DISEASE; FISHY ODOR; FLUSHING; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; HEART MUSCLE CONDUCTION DISTURBANCE; HEMOLYTIC ANEMIA; HUMAN; HYDRATION; HYPERBILIRUBINEMIA; HYPOTENSION; IMMUNE DEFICIENCY; KERNICTERUS; KIDNEY DISEASE; LABORATORY TEST; LIFESTYLE MODIFICATION; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LOADING DRUG DOSE; MELAS SYNDROME; METABOLIC ACIDOSIS; MUSCULOSKELETAL DISEASE; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NUTRITION; ODOR; OXIDATIVE PHOSPHORYLATION; PERIPHERAL NEUROPATHY; PHARMACEUTICAL CARE; POINT MUTATION; PROGNOSIS; RADIODIAGNOSIS; RESPIRATORY CHAIN; REVIEW; SHORT STATURE; SIDE EFFECT; TACHYCARDIA; VASCULAR DISEASE; VOMITING;

ADENOSINE TRIPHOSPHATE; DNA, MITOCHONDRIAL; HUMANS; MELAS SYNDROME; PHARMACEUTICAL SERVICES; POINT MUTATION;

EID: 78149309407     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.11.1179     Document Type: Review

References (62)

1. Sproule DM, Kaufmann P. Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome. Ann N Y Acad Sci 2008;1142:133-58.
2. Braunwald E, Fauci AS, Kasper DL, et al. Harrison's principles of internal medicine, 15th ed. In: Johns D, ed. Diseases caused by genetic defects of mitochondria. New York: McGraw-Hill, 2001:404-6.
3. Gvozdjáková A, ed. Mitochondrial medicine: mitochondrial metabolism, diseases, diagnosis, and therapy. New York: Springer Science, 2008:1-18, 115-24.
4. Taylor RW, Wardell TM, Lightowlers RN, Turnbull DM. Molecular basis for treatment of mitochondrial myopathies. Neurol Sci 2000;21(5 suppl):S909-12.
5. Hilton G. MELAS: a mitochondrial encephalomyopathy syndrome. J Neurosci Nurs 1995;27:278-82.
6. Scaglia F, Northrop JL. The mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options. CNS Drugs 2006;20:443-64.
7. Naini A, Kaufmann P, Shanske S, et al. Hypocitrullinemia in patients with MELAS: an insight into the "MELAS paradox." Neurol Sci 2005;229-230:187-93.
8. Shinmei Y, Kase M, Suzuki Y, et al. Ocular motor disorders in mitochondrial encephalopathy with lactic acid and stroke-like episodes with the 3271 (T-C) point mutation in mitochondrial DNA. J Neuroophthalmol 2007;27:22-8.
9. Thambisetty M, Newman NJ, Glass JD, et al. A practical approach to the diagnosis and management of MELAS: case report and review. Neurologist 2002;8:302-12.
10. Majamaa K, Moilanen JS, Uimonen S, et al. Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: prevalence of the mutation in an adult population. Am J Hum Genet 1998;63:447-54.
11. Neargarder SA, Murtagh MP, Wong B, et al. The neuropsychologic deficits of MELAS: evidence of global impairment. Cog Behav Neurol 2007;20:83-92. (Pubitemid 46905203)
12. Hirano M, Pavlakis SG. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts. J Child Neurol 1994;9:4-13. (Pubitemid 24022131)
13. Sproule DM, Kaufmann P, Engelstad K, et al. Wolff-Parkinson- White syndrome in patients with MELAS. Arch Neurol 2007;64:1625-7. (Pubitemid 350106764)
14. Betts J, Barron MJ, Needham SJ, et al. Gastrointestinal tract involvement associated with the 3243A>G mitochondrial DNA mutation. Neurology 2008;70:1290-2. (Pubitemid 351520953)
15. Sue CM, Mitchell P, Crimmins DS, et al. Pigmentary retinopathy associated with the mitochondrial DNA 3243 point mutation. Neurology 1997;49:1013-17. (Pubitemid 27456080)
16. Kaufmann P, Shungu DC, Sano MC, et al. Cerebral lactic acidosis correlates with neurological impairment in MELAS. Neurology 2004;62:1297-302. (Pubitemid 38526040)
17. Iizuka T, Sakai F, Kan S, Suzuki N. Slowly progressive spread of the stroke-like lesions in MELAS. Neurology 2003;61: 1238-44. (Pubitemid 37377544)
18. Montagna P, Gallassi R, Medori R, et al. MELAS syndrome: characteristic migrainous and epileptic features and maternal transmission. Neurology 1988;38:751-4.
19. Howard RS, Russell S, Losseff N, et al. Management of mitochondrial disease on an intensive care unit. QJM 1995;88:197-207.
20. Chinnery PF, Bindoff LA. 116th ENMC international workshop: the treatment of mitochondrial disorders. Neuromuscul Disord 2003;13:757-64.
21. Kadowaki T, Kadowaki H, Mori Y, et al. A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA. N Engl J Med 1994;330:962-8.
22. Tan TM, Caputo C, Medici F, et al. MELAS syndrome, diabetes, and thyroid disease: the role of mitochondrial oxidative stress. Clin Endocrinol 2009;70:339-41.
23. Koga Y, Akita Y, Junko N, et al. Endothelial dysfunction in MELAS improved by L-arginine supplementation. Neurology 2006;66:1766-9.
24. Marazita ML, Ploughman LM, Rawlings B, Remington E, Arnos KS, Nance WE. Genetic epidemiological studies of early-onset deafness in the U.S. school-age population. Am J Med Genet 1993;46:486-91.
25. Sue CM, Lipsett LJ, Crimmins DS, et al. Cochlear origin of hearing loss in MELAS syndrome. Ann Neurol 1998;43:350-9.
26. (Leu) gene (m.3243A>G). J Inherit Metab Dis 2008;64:625-7.
27. Karppa M, Syrjala P, Tolonen U, Majamaa K. Peripheral neuropathy in patients with the 3243A>G mutation in mitochondrial DNA. J Neurol 2003;250:216-21.
28. Karvonen SL, Haaapasaari KM, Kallioinen M, Oikarinen A, Hassinen IE, Majamaa K. Increased prevalence of vitiligo, but no evidence of premature ageing, in the skin of patients with bp 3243 mutation in mitochondrial DNA in the mitochondrial encephalopathy, lactic acidosis and stroke-like episodes syndrome (MELAS). Br J Dermatol 1999;140:634-9.
29. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006(1): CD002967.
30. Marriage B, Clandinin T, Glerum M. Nutritional cofactor treatment in mitochondrial disorders. J Am Diet Assoc 2003;103:1029-38.
31. Parikh S, Saneto R, Falk M, Anselm I, Cohen B, Haas R. A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol 2009;11:414-30.
32. Finsterer J. Management of mitochondrial stroke-like episodes. Eur Neurol 2009;16:1178-84.
33. Bandyopadhyay SK, Dutta A. Mitochondrial hepatopathies. J Assoc Physicians India 2005;53:973-8.
34. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990;322:1098-105.
35. Finsterer J, Startil U, Bittner R, Sporn P. Increased sensitivity to rocuronium and atracurium in mitochondrial myopathy. Can J Anaesth 1990;45:781-4.
36. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000;22:685-708. (Pubitemid 30451995)
37. Lin CM, Thajeb P. Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA. Metab Brain Dis 2007;22:105-9. (Pubitemid 46354826)
38. Rantikova LA, Cheistiakov VV. Possible biochemical mechanism of the toxic effects of barbiturates. Biokhimiia 1978;43:1989-93.
39. Thomas JE, Lee N, Thompson PD. Statins provoking MELAS syndrome. Eur Neurol 2007;57:232-5.
40. Vorobjev IA, Zorov DB. Diazepam inhibits cell respiration and induces fragmentation of mitochondrial reticulum. FEBS Lett 1983;163:311-14.
41. Clay S, Behnia M, Brown K. Mitochondrial disease: a pulmonary and critical care perspective. Chest 2001;120:634-48. (Pubitemid 32881287)
42. Gold D, Cohen B. Treatment of mitochondrial cytopathies. Semin Neurol 2001;21:309-26.
43. Kerr D. Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol Genet Metab 2010;99:246-55.
44. 10 with multiple vitamins is generally effective in treatment of mitochondrial disease. Neurology 1993;43:884-90.
45. 10 treatment in mitochondrial encephalomyopathies: short-term double-blind crossover study. Eur Neurol 1997;37:212-18.
46. Chinnery P, Majamaa K, Turnbull D, Thorburn D. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2006(1):CD004426.
47. Koga Y, Akita Y, Nishioka J, et al. L-Arginine improves the symptoms of stroke-like episodes in MELAS. Neurology 2005;64:710-12. (Pubitemid 40261903)
48. Koga Y, Akita Y, Nishioka J, et al. MELAS and L-arginine therapy. Mitochondrion 2007;7:133-9.
49. Penn AM, Lee JW, Thuillier P, et al. MELAS syndrome with mitochondrial tRNA (Leu) (UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 1992;42:2147-52.
50. Remes AM, Liimatta EV, Winqvist S, et al. Ubiquinone and nicotinamide treatment of patients with the 3243A→G mtDNA mutation. Neurology 2002;59:1275-7. (Pubitemid 35192409)
51. Tarnopolsky MA. Clinical use of creatine in neuromuscular and neurometabolic disorders. Subcell Biochem 2007;46:183-204.
52. Kurogouchi F, Oguchi T, Matawari E, et al. A case of mitochondrial cytopathy with a typical point mutation for MELAS presenting with severe focal-segmental glomerulosclerosis as main clinical manifestation. Am J Nephrol 1998;18:551-6.
53. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 1997;20:1502-9.
54. 10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007;25:235-42.
55. Ikejiri Y, Mori E, Ishii K, Nishimoto K, Yasuda M, Sasaki M. Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS. Neurology 1996;47: 583-5. (Pubitemid 26324069)
56. Napolitano A, Salvetti S, Vista M, Lombardi V, Siciliano G, Giraldi C. Long-term treatment with idebenone and riboflavin in a patient with MELAS. Neurol Sci 2000;21(5 suppl):S981-2.
57. Stacpoole PW, Harwood HJ Jr, Cameron DF, et al. Chronic toxicity of dichloroacetate: possible relation to thiamine deficiency in rats. Fundam Appl Toxicol 1990;14:327-37.
58. Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006;66:324-30.
59. Tanaka J, Nagai T, Arai H, et al. Treatment of mitochondrial encephalomyopathy with a combination of cytochrome c and vitamins B1 and B2. Brain Dev 1997;19:262-7.
60. Rossi FH, Okun M, Yachnis A, Quisling R, Triggs W. Corticosteroid treatment of mitochondrial encephalomyopathies. Neurologist 2002;8:313-15.
61. Ichiki T, Tanaka M, Nishikimi M, et al. Deficiency of subunits of complex I and mitochondrial encephalomyopathy. Ann Neurol 1988;23:287-94. (Pubitemid 18086158)
62. Oguro H, Iijima K, Takahashi K, et al. Successful treatment with succinate in a patient with MELAS. Intern Med 2004;43: 427-31.